PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background We conducted a systematic review and meta-analysis to dissect the association between PIK3CA mutations and resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) according to PIK3CA exon of mutations in metastatic colorectal cancer (mCRC).Methods We systematically identified studies exploring the association between PIK3CA mutations and clinical outcomes of mCRC patients treated with anti-EGFR MoAbs. The primary clinical outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). The pooled relative risk (RR) or hazard ratio (HR) was estimated by using fixed effect model or random effect model according to heterogeneity between studies.Results Thirteen studies were considered eligible, with 576 mCRC patients included. In KRAS wild-type mCRC patients, we observed a lower ORR in patients with PIK3CA exon 20 mutations [3 studies, 377 patients; ORR = 0% versus 37%; RR = 0.25; 95% confidence interval (CI) 0.05-1.19; P = 0.082], although the result was not statistically significant because of the small sample size. Only one study provided survival data according to the PIK3CA exon of the mutations, in which PIK3CA exon 20 mutations were statistically significantly associated with shorter PFS (HR = 2.52; 95% CI 1.33-4.78; P = 0.013) and OS (HR = 3.29; 95% CI 1.60-6.74; P = 0.006) in KRAS wild-type mCRC patients treated with anti-EGFR MoAbs. The predictive power of exon 20 mutation is greater than exon 9 mutations and all exons mutations in terms of ORR, PFS, and OS.Conclusion These analyses suggest that PIK3CA exon 20 mutations may be a potential biomarker for resistance to anti-EGFR MoAbs in KRAS wild-type mCRC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, PIK3CA exon 20 mutations significantly reduced the anti-EGFR response rate in the case of KRAS-WT, while exon 9 mutations had no significant effect [167,168].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [168]
In the citing paper
“The most common mutations in PIK3CA are in exons 9 (68.5%) and 20 (20.4%), and they are detected in 10–18% of mCRC [11, 105].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [105]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“10) was found and cannot be explained [27].”
BackgroundThe combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · cited 1×
“Heterogeneity was assessed by the Q-test with a df equal to the number of included studies minus one [26].”
MethodCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Recently, two monoclonal antibodies (MoAbs) targeted at epidermal growth factor receptor (EGFR), the chimeric immunoglobulin G1 MoAb cetuximab and the fully humanized immunoglobulin G2 panitumumab, were found effective in combination with chemotherapy or as single therapeutic agent for chemotherapy-resistant mCRC [2,…”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Modern Epidemiology 3rd edition
Rothman, K. J., Lash, T. L., & Greenland, S. (1986) · Cited by 3,098
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · cited 2×
“PIK3CA mutations are observed in some 10%–18% of CRC patients, mainly occurred in exon 9 (E542K, E545K) and exon 20 (H1047R) [13, 14].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 22×
“Five studies for KRAS wild-type patients all reported a shorter median PFS [21, 23] or OS [21, 23, 24] in PIK3CA mutant patients than in PIK3CA wild patients, although none of the results was statistically significant.”
BackgroundMethodResultInfluentialRothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Cited by
Items 101–189 of 189
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 23
Phipps, A. I., Ahnen, D. J., Cheng, I. C., Newcomb, P. A., Win, A. K., & Burnett, T. S. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0204 · Cited by 21
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Mardjuadi, F. I., Carrasco, J., Coche, J.-C., Sempoux, C. L., Jouret‐Mourin, A., Scalliet, P. G. M., Goeminne, J., Daisne, J., Delaunoit, T., Vuylsteke, P., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0342-9 · Cited by 21
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 23
Yu, Q., Jiang, H., Su, X., Jiang, Z., Liang, X., Zhang, C., Shang, W., Zhang, Y., Chen, H., Yang, Z., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.03.002 · Cited by 23
Self-citationExploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 24
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 20
Shen, W., Chen, H., & Liu, P. (2014) · Chinese Journal of Cancer Research · doi:10.3978/j.issn.1000-9604.2014.01.10 · Cited by 21
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas
Marchiò, C., Filippo, M. R. D., Ng, C. K. Y., Piscuoglio, S., Soslow, R. A., Reis-Filho, J. S., & Weigelt, B. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.010 · Cited by 18
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
Kim, S. T., Lira, M., Deng, S., Lee, S., Park, Y. S., Lim, H. Y., Kang, W. K., Mao, M., Heo, J. S., Kwon, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5432 · Cited by 20
Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer
Ronnekleiv‐Kelly, S. M., Burkhart, R. A., & Pawlik, T. M. (2016) · Surgical Oncology · doi:10.1016/j.suronc.2016.05.018 · Cited by 24
Molecular Evaluation of Colorectal Adenocarcinoma
Nowak, J. A., & Hornick, J. L. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.007 · Cited by 21
Wu, J., Li, X., Liu, H., Liu, Y.-J., & Liu, X. (2023) · Biomedical Reports · doi:10.3892/br.2023.1686 · Cited by 20
Kim, J. S., Kim, J. E., Kim, K., Lee, J., Park, J. O., Lim, H. Y., Park, Y. S., Kang, W. K., & Kim, S. T. (2017) · Journal of Cancer · doi:10.7150/jca.19458 · Cited by 17
Shuford, R. A., Cairns, A., & Moaven, O. (2020) · Cancers · doi:10.3390/cancers12113481 · Cited by 18
González‐González, M., García, J. G., Montero, J. A. A., Fernandez, L. M. G., Bengoechea, Ó., Muñez, O. B., Órfão, A., Sayagués, J. M., & Fuentes, M. (2013) · PubMed · Cited by 16
Torén, W., Ansari, D., & Andersson, R. E. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0715-8 · Cited by 15
Natalicchio, M. I., Improta, G., Zupa, A., Cursio, O. E., Stampone, E., Possidente, L., Gerardi, A. M. T., Vita, G., Martini, M., Cassano, A., et al. (2014) · Future Oncology · doi:10.2217/fon.13.233 · Cited by 16
Abbasabadi, Z. M., Asl, D. H., Rahmani, B., Shahbadori, R., Karami, S., Peymani, A., Taghizadeh, S., & Samiee-Rad, F. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24868 · Cited by 21
Li, W., Hu, T., Zhou, L., Feng, Y., Wang, Y., & Jin, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2493-9 · Cited by 16
Huang, Q., Jing, Y., Xiong, L., Li, L., Feng, J., & Cheng, J. G. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06640-x · Cited by 19
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 18
Wu, S., Wen, F., Li, Y., Gao, X., He, S., Liu, M., Zhang, X., & Tian, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-4691-5 · Cited by 13
Mack, E., Stabla, K., Riera‐Knorrenschild, J., Moll, R., Neubauer, A., & Brendel, C. A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2589-2 · Cited by 13
Personeni, N., Rimassa, L., Verusio, C., Barni, S., Rubino, L., Bozzarelli, S., Villa, E., Carnaghi, C., Tronconi, M. C., Gerardi, C., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.02.006 · Cited by 13
Precision Medicine in Colorectal Cancer: Evolving Genomic Landscape and Emerging Consensus
Fisher, K. W., Antonio Lopez-beltran, B., Montironi, R., & Liang Cheng, C. (2015) · Future Oncology · doi:10.2217/fon.15.219 · Cited by 11
Ren, L., Zhu, D., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, R., Ye, Y., Zhang, S., et al. (2023) · Clinical Surgical Oncology · doi:10.1016/j.cson.2023.100013 · Cited by 12
Sultan, M. H., Zhang, Q., Wang, Y., Xia, Y., & Jia, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5545 · Cited by 11
Taniguchi, H., Uehara, K., Nakayama, G., Nakayama, H., Aiba, T., Hattori, N., Kataoka, M., Nakano, Y., Kawase, Y., Okochi, O., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100786 · Cited by 12
Colorectal Cancer in the Arab World
Alzaabi, A. A. (2022) · Springer eBooks · doi:10.1007/978-981-16-7945-2_23 · Cited by 10
Comparative mutational analysis of distal colon cancer with rectal cancer
Zhang, Z., Wang, A., Tang, X., Chen, Y., Tang, E., & Jiang, H. (2020) · Oncology Letters · doi:10.3892/ol.2020.11269 · Cited by 9
Peng, K., Liu, Y., Liu, S., Wang, Z., Zhang, H., He, W., Jin, Y., Wang, L., Xia, X., & Xia, L. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00916-y · Cited by 9
McGregor, M., & Price, T. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0711 · Cited by 10
Molecular testing in colorectal cancer
Thomas, J. S., & Shi, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00018-3 · Cited by 7
Fakih, M. (2013) · Future Oncology · doi:10.2217/fon.12.204 · Cited by 7
de Biase, D., Malapelle, U., Leo, A. D., Maloberti, T., Visani, M., Pisapia, P., Acquaviva, G., Pepe, F., Russo, G., Iaccarino, A., et al. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207468 · Cited by 7
Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer
Lu, Y., Gu, D., Zhao, C., Sun, Y., Li, W., He, L., Wang, X., Kou, Z., Jiang, S., & Guo, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160052 · Cited by 10
Shan, L., Li, M., Ma, J., & Zhang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107926 · Cited by 8
Takahashi, N., Yamada, Y., Taniguchi, H., Honma, Y., Iwasa, S., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.05.004 · Cited by 7
Sobani, Z. A., Sawant, A. S., Jafri, M., Correa, A. K., & Şahin, İ. H. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.340 · Cited by 10
Clinical biomarkers in colorectal cancer.
Morris, V. K., & Kopetz, S. (2013) · PubMed · Cited by 7
Prognostic gene expression profile of colorectal cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Baldaniya, L., Ballal, S., Vashishth, R., Parmar, M., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149433 · Cited by 6
The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien, K., Berry, S. R., Ko, Y., & Chan, K. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.982100 · Cited by 6
Tayshetye, P., Miller, K. E., Monga, D. K., Brem, C. E., Silverman, J. F., & Finley, G. G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00314 · Cited by 6
Afrăsânie, V. A., Marinca, M. V., Gafton, B., Rusu, A., Froicu, E.-M., Sur, D. G., Lungulescu, C. V., Popa, R. C., Afrăsânie, I., Ivanov, A. V., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1557609 · Cited by 6
Melloni, G. E. M., Guida, A., Curigliano, G., Botteri, E., Espósito, A., Kamal, M., Tourneau, C. L., Riva, L., Magi, A., Maria, R. D., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00015 · Cited by 4
Oncogenic mutations of clinical significance in colorectal cancer
Lea, V., Lim, S. H.-S., & Lee, C. S. (2025) · Pathology · doi:10.1016/j.pathol.2025.05.001 · Cited by 4
Biomarkers and Targeted Therapeutics in Colorectal Cancer
Meguerditchian, A. N., & Dunn, K. B. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.07.002 · Cited by 4
THE ROLE OF PHOSPHATIDYLINOSITOL-3-KINASE IN CARCINOGENESIS
Oskina, N., Shcherbakov, A., Filipenko, M., Kushlinskiy, N., & Овчинникова, Л. П. (2017) · Voprosy Onkologii · doi:10.37469/0507-3758-2017-63-4-545-556 · Cited by 4
Assessing colorectal cancer heterogeneity: one step closer to tailored medicine
Pitule, P., Čedíková, M., Třeška, V., Králíčková, M., & Liška, V. (2013) · Journal of Applied Biomedicine · doi:10.2478/v10136-012-0035-6 · Cited by 6
Chowdhury, S., Ara, S. J. F., Mili, S. M., Momotaz, T., Molla, M. M. A., Anwar, S., & Saleh, A. A. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100054 · Cited by 6
Navarro, S., Pérez‐Segura, P., y Cajal, S. R., Salazar, R., García‐Foncillas, J., Musulén, E., García‐Carbonero, R., Payá, A., & Alfonso, P. G. (2012) · Revista Española de Patología · doi:10.1016/j.patol.2012.05.001 · Cited by 14
Koçoğlu, H., Velibeyoglu, F. M., Karaca, M., & Tural, D. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.1 · Cited by 7
Ding, C., Yao, R., Wang, Y., Liu, H., Li, C., & Xie, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656372 · Cited by 7
Valladares, C. T., Valenzuela, G., González, E., Maureira, I., Toro, J., Freire, M., Sepúlveda-Hermosilla, G., Ampuero, D., Blanco, A., Gallegos, I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094695 · Cited by 5
A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer
Hansen, T. F., Andersen, R. F., Pallisgaard, N., Spindler, K. G., Mortensen, J. P., Keldsen, N., Lindebjerg, J., Sørensen, F. B., & Jakobsen, A. K. M. (2014) · Colorectal Cancer · doi:10.2217/crc.13.85 · Cited by 3
Ohta, R., Yamada, T., Nakamura, M., Enomoto, M., Takahashi, M., Yokomizo, H., Kosugi, C., Ishimaru, K., Sonoda, H., Kuramochi, H., et al. (2023) · Digestion · doi:10.1159/000528283 · Cited by 3
Current Perspective and Treatment Strategies in Targeted Therapy for Colorectal Cancer
Maurya, P. K., & Mani, A. (2024) · Clinical Cancer Drugs · doi:10.2174/012212697x308365240529100442 · Cited by 4
Sakthianandeswaren, A., Sabljak, P., Elliott, M. J., Palmieri, M., & Sieber, O. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80690 · Cited by 3
Oscorbin, I. P., Beginyazova, O., Khlistun, I. V., Shamovskaya, D. V., Oskina, N. A., & Филипенко, М. Л. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11804 · Cited by 6
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 3
Fan, J., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., 张苏展, et al. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00062-6 · Cited by 3
Zeng, M., Feng, Q., Lu, M. S., Zhou, J., Yang, Z., & Tang, J.-L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168418 · Cited by 3
Self-citationFrequent intragenic rearrangements of DPYD in colorectal tumours
Kuilenburg, A. B. P., Etienne-Grimaldi, M.-C., Mahamat, A., Meijer, J., Laurent‐Puig, P., Olschwang, S., Gaub, M.-P., Hennekam, R. C. M., Benchimol, D., Houry, S., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.68 · Cited by 2
Biomarkers in Gastrointestinal System Carcinomas
Pehlivanoğlu, B., & Ünlü, Ş. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-84432-5_7 · Cited by 1
Karapetis, C. S., Maru, D., Waring, P. M., Tie, J., & Michael, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1052797 · Cited by 2
Napolitano, T. T. S. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s10-001
Tao, H., Shen, M., Zhang, X., Wang, M., Wu, Y., Sun, H., Chen, L., Yang, Y., Chen, K., & Li, D. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1237 · Cited by 1
Current drug therapy for colorectal cancer
Mohapatra, L., Tripathi, A. S., Alka, Mishra, D. K., Parida, S. K., Yasir, M., Maurya, R. K., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00014-3 · Cited by 2
Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer
Çiftçi, R., & Tural, D. G. (2016) · InTech eBooks · doi:10.5772/62304 · Cited by 1
Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks
Bairi, K. E., Lengyel, C. G., Marra, A., & Afqir, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-53821-7_2 · Cited by 1
O’Gorman, C. (2014) · SETU Waterford Libraries - Open Access Repository
Marqueurs moléculaires prédictifs de réponse aux thérapies ciblées dans les cancers digestifs
Perkins, G. (2012) · theses.fr (ABES) · doi:10.70675/5b4631efzc0e5z4dddz8408z43ab410793f3
What is the future potential of the PI3K pathway in colorectal cancer treatment?
Palmieri, M., Desai, J., & Sieber, O. M. (2014) · Colorectal Cancer · doi:10.2217/crc.14.11
Ciombor, K. K., & Goldberg, R. M. (2014) · Hepatic Oncology · doi:10.2217/hep.14.13
Biomarkers Molecular biomarkers in colorectal cancer in pursuit of personalizing treatment
Lai, S. M., Oseran, A. S., & Marshall, J. L. (2014)
Half, E., Fokra, A., & Arber, N. (2016) · Springer eBooks · doi:10.1007/978-3-319-33889-7_15
Systemic inflammation markers in blood samples of colorectal cancer patients
Grudzińska, M., Jakubowska, K., Koda, M., Koda, L., Kisielewski, W., Smereczański, N., Rogoz-Jezierska, N., & FAMULSKI, W. (2020) · Progress in Health Sciences · doi:10.5604/01.3001.0014.1917
Wu, J., Li, X., Liu, H., Liu, Y.-J., & Liu, X. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4201028
ONCOGENE RAS E CÂNCER COLORRETAL: UMA REVISÃO DE LITERATURA
Trevisan, G. A., Fracon, B. R. R., Pereira, D. C., Cezário, F. G., Beja, G. B. S. P., & Santos, L. A. (2023) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v4i11.4320
Pathology in Oncology Practice
Shet, T. M., Pai, T., Roy, P., & Paulose, R. R. (2025) · Springer eBooks · doi:10.1007/978-981-97-8389-2_6
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26641327
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.24580446
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26641330
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24580296
Shao, Y., Zhang, Z., Wang, Y., Zhang, C., Liu, E., & Yu, H. (2026) · Targetome · doi:10.48130/targetome-0025-0012
Predictive biomarkers in clinical practice in colorectal cancer
Rodríguez-Castells, M., & Élez, E. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00131
Doermann, A. S., Caspi, A., Evans, A. E., Feci, A., Entezari, A. A., Snook, A. E., & Waldman, S. A. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683096 · Cited by 1
Colorectal Cancer Biomarkers: The Expanding Landscape
Rakoczy, K., Herbetko, A., Suwała, S., Czarny, J., Rudno‐Rudzińska, J., Milbrandt, O., & Kulbacka, J. (2026) · Cells · doi:10.3390/cells15211979
Metadata
- Authors
- Mao, C., Yang, Z. Y., Hu, X. F., Chen, Q., & Tang, J. L.
- Affiliations
- Chinese University of Hong Kong (HK)
- Southern Medical University (CN)
- Corresponding author
- Tang, J.L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 1518-1525
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2108455517
- Cited by
- 188
- References
- 38
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 10 · 2023: 12 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 11 · 2016: 24 · 2015: 17 · 2014: 25 · 2013: 20 · 2012: 10
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2730 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Health and Health Services Research Fund (HHSRF 09100561)
- from Food and Health Bureau of Hong Kong
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-EGFR monoclonal antibody, KRAS wild-type, metastatic colorectal cancer, drug resistance, predictive biomarkers, objective response rate, progression-free survival, overall survival
- MeSH terms
- Cetuximab, Panitumumab, Antibodies, Monoclonal, Antineoplastic Agents, Exons, Humans, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins, Retrospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Genetic Association Studies, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.